Rabeprazole sodium

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Frequent Heartburn

Conditions

Frequent Heartburn

Trial Timeline

Apr 1, 2006 → Jan 1, 2007

NCT ID

NCT01286194

About Rabeprazole sodium

Rabeprazole sodium is a pre-clinical stage product being developed by Eisai for Frequent Heartburn. The current trial status is completed. This product is registered under clinical trial identifier NCT01286194. Target conditions include Frequent Heartburn.

What happened to similar drugs?

0 of 1 similar drugs in Frequent Heartburn were approved

Approved (0) Terminated (0) Active (1)

🔄Lansoprazole + Lansoprazole + placeboNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01264822	Pre-clinical	Completed	Jan 13, 2011	Nov 17, 2016	Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive
NCT01321567	Pre-clinical	Completed	Jan 1, 2011	Aug 1, 2013	Refractory Reflux Esophagitis
NCT00855361	Phase 1	Completed	Jul 1, 2009	Dec 1, 2011	Gastroesophageal Reflux
NCT00747695	Phase 1	Completed	Mar 1, 2008	Sep 1, 2009	GERD
NCT01286194	Pre-clinical	Completed	Apr 1, 2006	Jan 1, 2007	Frequent Heartburn
NCT00236184	Phase 3	Completed	Oct 1, 2005	Jun 1, 2008	Heartburn
NCT00132496	Phase 2	Completed	Aug 1, 2005	Jul 1, 2006	Gastroesophageal Reflux Disease

Competing Products

1 competing product in Frequent Heartburn

See all competitors

Product	Company	Stage	Hype Score
Lansoprazole + Lansoprazole + placebo	Novartis	Phase 3	40